March 2011
SUMMARY
DECISION SUPPORT
GOAL
LDL CHOLESTEROL
HDL CHOLESTEROL
ALERTS
Low risk
<160
Moderate Risk
<130
High Risk
<130
Men
>40 mg/dl
Women
>50 mg/dl
TRIGLYCERIDES
<150 mg/dl
DIAGNOSTIC CRITERIA/EVALUATION
Obtain Lipid Panel after 9-12 hours fasting
Determine presence of CHD or CHD equivalents (i.e DM, PVD, CAD, CKD, AAA)
Determine number of CV risk factors if >2, and no CHD equivalent assess 10 year risk of CHD. (*see Framingham tables or use Framingham calculator to determine risk category)
H&P: rule out secondary causes (DM, renal disease, thyroid disorder, obstructive liver disease, drugs, obesity).
Baseline labs: UA, TSH, glucose, LFTs, Serum Cr, BUN
TREATMENT OPTIONS
Initiate therapeutic lifestyle changes (TLC) such as diet, exercise, wt loss if BMI >25 if LDL is above goal.
A 3 month trial of TLC appropriate unless LDL 220
Consider adding drug therapy if LDL exceeds goal for patient
If CHD equivalent may start drug right away, lower risk can try 3 months trial TLC first
Identify metabolic syndrome and treat, if present, after 3 months of TLC.
Treat elevated triglycerides as per ATP III algorithm on page 3.
MONITORING
Patients on TLC only should have a repeat lipid panel 3 months after TLC initiation.
After the initial follow-up visit, patients may be seen at 3 month intervals until target LDL goal is reached.
Check LFTs as clinically indicated, usually check 3 mos after reaching maximum statin dose. If LFTs increase,
monitor until normalize, if consistently > 3X normal- stop statin.
Once at goal, lipids and LFTs should be monitored at 6-12 month intervals.
If a patient has achieved treatment goals and is clinically stable on at least 2 consecutive encounters , the patient
may be reevaluated every 180 days unless the PCP determines the patient needs more frequent monitoring.
Informationcontainedintheguidelinesisnotasubstituteforahealthcareprofessional'sclinicaljudgment.Evaluationandtreatmentshouldbetailoredtothe
individualpatientandtheclinicalcircumstances.Furthermore,usingthisinformationwillnotguaranteeaspecificoutcomeforeachpatient.
March 2011
SUMMARY
DECISION SUPPORT
MEDICATIONS:
DRUG CLASS
HMG COA
REDUCTASE
INHIBITORS
LIPID/LIPOPROTEIN
EFFECTS
As a class:
Second Line:
Atorvastatin+ (Lipitor) (10-80 mg)
(20 mg lowers LDL average of 46%)
(+ Will be generic in late 2011 currently
nonformulary)
LDL-C
18-55%
HDL-C
5-15%
TG
7-30%
(STATINS)
SIDE EFFECTS
Myopathy
Increased liver
enzymes
Special Indication:
Pravastatin (Pravachol) (20-40 mg)
(20 mg lowers LDL average of 24%)
This is drug of choice if patient on protease inhibitor or other strong CYP34A
inhibitor
Cholestyramine (4-16 g)
LDL-C
15-30%
HDL-C
3-5%
TG
No change or
increase
NICOTINIC ACID
FIBRIC ACIDS
Absolute:
Active or chronic liver disease
Pregnancy
Drug interactions:
Statins (except pravastatin
and rosuvastatin) are metabolized by cytochrome P-450
34A (CYP34A)so do not
give most statins (except
pravastatin) with drugs that
block CYP34A including:
Protease inhibitors
Macrolide antibiotics
Some anti-fungals
Cyclosporine
BILE ACID
SEQUESTRANTS
CONTRAINDICATIONS
LDL-C
5-25%
HDL-C
15-35%
TG
20-50%
LDL-C
5-20%
(may be increased in
patients with high
TG)
HDL-C
TG
Gastrointestinal distress
Constipation
Decreased
absorption of
other drugs
Absolute:
dysbeta-lipoproteinemia
TG >400 mg/dL
Flushing
Hyperglycemia
Hyperuricemia
(or gout)
Upper GI distress
Hepatotoxicity
Absolute:
Chronic liver disease
Severe gout
Dyspepsia
Gallstones
Myopathy
Absolute:
Severe renal disease
Severe hepatic disease
Relative:
TG >200 mg/dL
Relative:
Diabetes, PUD or
Hyperuricemia
10-20%
20-50%
Major Risk Factors (Exclusive of LDL Cholesterol) That Modify LDL Goals
Cigarette smoking
Family history of premature CHD (CHD in male first degree relative <55 years;
* HDL cholesterol >60 mg/dL counts as a negative risk factor; its presence removes one risk factor from the total count.
March 2011
SUMMARY
10
11
12
13
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
-1
60+
50-59
40-49
<40
<120
120-129
130-139
140-159
160+
Systolic BP If Untreated
If Treated
Points
HDL
11
Age 20-39
0
3
40-49 50-59
4%
5%
6%
8%
10%
12%
16%
20%
25%
8
9
10
11
12
13
14
15
16
30%
3%
17 or more
2%
1%
3
2%
1%
1%
1%
1%
< 1%
10-Year Risk
<0
Point Total
60-69 70-79
Smoker
Nonsmoker
280+
240-279
200-239
160-199
16
14
12
10
-3
-1
Points
140159
160+
130139
120129
<120
Systolic If
If
BP
Untreated Treated
<40
40-49
50-59
60+
HDL
75-79
70-74
65-69
60-64
55-59
50-54
45-49
40-44
35-39
8
11
13
160-199
200-239
240-279
280+
10
Age
50-59
Age
60-69
Age
70-79
4049
5059
6069
17%
25 or more
24
30%
27%
22%
14%
22
23
11%
8%
21
6%
19
20
5%
4%
18
3%
16
17
2%
2%
13
15
1%
12
14
1%
11
1%
1%
9
10
< 1%
<9
Smoker
Nonsmoker 0
Age 2039
7079
0
4
<160
Age
40-49
Age
20-39
-7
Points
Total
Cholesterol
20-34
Age
DECISION SUPPORT
-4
35-39
SUMMARY
<160
70-79
-9
60-69
20-34
50-59
Points
Age
40-49
March 2011
March 2011
SUMMARY
DECISION SUPPORT
March 2011
SUMMARY
DECISION SUPPORT
every 5 years.
Your doctor may test you more often if your cholesterol levels are
high.
Talk to your doctor about what your cholesterol numbers mean.
Be alert!
Blood Pressure:
Weight:
BP: _____/_____
My weight: _________
BMI: (18.5-24.9)_________
BP Goal:_____/_____
My BP goal: _____________
Eat more fruits, vegetables, and whole grains when possible.
Drink water or sugar-free beverages instead of regular soda
MEDICATION
METABOLIC SYNDROME